Entero Therapeutics, Inc. (NASDAQ:GRDX) Short Interest Down 41.2% in June

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 43,189 shares, a decline of 41.2% from the May 31st total of 73,503 shares. Based on an average daily volume of 123,990 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.7% of the shares of the company are sold short.

Entero Therapeutics Trading Up 0.7%

Entero Therapeutics stock traded up $0.03 during trading hours on Thursday, reaching $4.48. 16,092 shares of the company were exchanged, compared to its average volume of 124,541. Entero Therapeutics has a 12 month low of $1.08 and a 12 month high of $6.93. The firm has a 50-day moving average price of $4.32. The firm has a market capitalization of $29.79 million, a price-to-earnings ratio of -2.39 and a beta of 1.81.

Entero Therapeutics (NASDAQ:GRDX) last released its quarterly earnings results on Wednesday, May 27th. The company reported ($0.82) EPS for the quarter. The firm had revenue of $0.04 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Entero Therapeutics stock. DRW Securities LLC purchased a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned 1.45% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 12.30% of the company’s stock.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.